Your browser does not support JavaScript capabilities, which maybe required to display this page properly.


PDF FormatRequires Adobe Acrobat Reader

Table 11.6c

Immunosuppression Use for Induction by Steroid Use at Discharge, 2003 to 2007

Recipients with Heart Transplants

  No Steroids Used for Maintenance Steroids Used for Maintenance
N % N %
Functioning Graft with Immunosuppression Info at Discharge 805 100.0% 8,912 100.0%
Induction Drugs        
Atgam/NRATG/NRATS 78 9.7% 488 5.5%
OKT3 17 2.1% 292 3.3%
Thymoglobulin 208 25.8% 1,371 15.4%
Zenapax 71 8.8% 1,329 14.9%
Simulect 45 5.6% 1,177 13.2%
Campath 98 12.2% 35 0.4%
Rituximab     22 0.2%
No Induction Drug Reported 296 36.8% 4,493 50.4%


Source: OPTN/SRTR Data as of May 1, 2008.

Includes patients with a functioning graft at discharge.

Steroids used for induction are not counted.

Individual induction drug percentages will not necessarily add up to 100 percent, as patients may be prescribed more than one induction drug.



PDF FormatRequires Adobe Acrobat Reader